CA3189383A1 - Combination therapy for treating abnormal cell growth - Google Patents
Combination therapy for treating abnormal cell growthInfo
- Publication number
- CA3189383A1 CA3189383A1 CA3189383A CA3189383A CA3189383A1 CA 3189383 A1 CA3189383 A1 CA 3189383A1 CA 3189383 A CA3189383 A CA 3189383A CA 3189383 A CA3189383 A CA 3189383A CA 3189383 A1 CA3189383 A1 CA 3189383A1
- Authority
- CA
- Canada
- Prior art keywords
- dosed
- cancer
- inhibitor
- antibody
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051320P | 2020-07-13 | 2020-07-13 | |
| US63/051,320 | 2020-07-13 | ||
| PCT/US2021/041439 WO2022015736A1 (en) | 2020-07-13 | 2021-07-13 | Combination therapy for treating abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3189383A1 true CA3189383A1 (en) | 2022-01-20 |
Family
ID=79554253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3189383A Pending CA3189383A1 (en) | 2020-07-13 | 2021-07-13 | Combination therapy for treating abnormal cell growth |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230330088A1 (https=) |
| EP (1) | EP4178573A4 (https=) |
| JP (1) | JP2023534009A (https=) |
| KR (1) | KR20230039684A (https=) |
| CN (1) | CN116056699A (https=) |
| AU (1) | AU2021307410A1 (https=) |
| BR (1) | BR112023000675A2 (https=) |
| CA (1) | CA3189383A1 (https=) |
| IL (1) | IL299789A (https=) |
| MX (1) | MX2023000589A (https=) |
| WO (1) | WO2022015736A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7582694B2 (ja) | 2020-01-10 | 2024-11-13 | イミューニヤリング コーポレーション | Ｍｅｋ阻害剤及びその治療的使用 |
| TW202329967A (zh) * | 2022-01-21 | 2023-08-01 | 大陸商應世生物科技（南京）有限公司 | 治療腫瘤的藥物組合及用途 |
| CN116120461B (zh) * | 2022-04-29 | 2023-09-29 | 德琪(杭州)生物有限公司 | 新型抗药抗体以及其用途 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| CN119947725A (zh) * | 2022-09-30 | 2025-05-06 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
| WO2024178274A2 (en) * | 2023-02-24 | 2024-08-29 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods of degrading raf(raf) protein in cells using mitogen-activated protein kinase kinase 1/2 (mek1/2) protein degraders |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025079712A1 (ja) * | 2023-10-12 | 2025-04-17 | 中外製薬株式会社 | ドライバー変異を有するがん患者における分子標的薬併用療法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6238459B2 (ja) * | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| US20170112865A1 (en) * | 2014-05-21 | 2017-04-27 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| SG11201700074YA (en) * | 2014-07-15 | 2017-02-27 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| JP2018519327A (ja) * | 2015-06-29 | 2018-07-19 | ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． | 治療用組成物、組合せ物および使用の方法 |
| CN109663130B (zh) * | 2017-10-13 | 2021-06-29 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 |
| WO2021047783A1 (en) * | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
-
2021
- 2021-07-13 AU AU2021307410A patent/AU2021307410A1/en active Pending
- 2021-07-13 MX MX2023000589A patent/MX2023000589A/es unknown
- 2021-07-13 CN CN202180049487.0A patent/CN116056699A/zh active Pending
- 2021-07-13 WO PCT/US2021/041439 patent/WO2022015736A1/en not_active Ceased
- 2021-07-13 BR BR112023000675A patent/BR112023000675A2/pt unknown
- 2021-07-13 JP JP2023501802A patent/JP2023534009A/ja active Pending
- 2021-07-13 US US18/005,012 patent/US20230330088A1/en active Pending
- 2021-07-13 KR KR1020237004543A patent/KR20230039684A/ko active Pending
- 2021-07-13 EP EP21841921.6A patent/EP4178573A4/en active Pending
- 2021-07-13 CA CA3189383A patent/CA3189383A1/en active Pending
- 2021-07-13 IL IL299789A patent/IL299789A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023000589A (es) | 2023-02-13 |
| BR112023000675A2 (pt) | 2023-04-25 |
| JP2023534009A (ja) | 2023-08-07 |
| IL299789A (en) | 2023-03-01 |
| AU2021307410A1 (en) | 2023-02-09 |
| KR20230039684A (ko) | 2023-03-21 |
| WO2022015736A9 (en) | 2022-05-05 |
| WO2022015736A1 (en) | 2022-01-20 |
| EP4178573A4 (en) | 2024-08-07 |
| CN116056699A (zh) | 2023-05-02 |
| US20230330088A1 (en) | 2023-10-19 |
| EP4178573A1 (en) | 2023-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230330088A1 (en) | Combination therapy for treating abnormal cell growth | |
| US20230103007A1 (en) | Combination therapy for treating abnormal cell growth | |
| US12280050B2 (en) | Therapeutic compositions, combinations, and methods of use | |
| US20250049792A1 (en) | Combination therapy for treating abnormal cell growth | |
| US20230201198A1 (en) | Methods of treating abnormal cell growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240719 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240719 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250707 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250707 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250711 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250711 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250711 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250714 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250917 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250917 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250917 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250917 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251127 |